Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/01.meg.0000280175.79379.04 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Hepatitis B and C infection in HIV-infected children and young adults attending HIV treatment centres in Calabar, Nigeria.
J Infect Dev Ctries
December 2024
Department of Paediatrics, University of Calabar, Calabar, Cross River State, Nigeria.
Introduction: Globally, approximately 2.7 million and 2.3 million people living with HIV are co-infected with hepatitis B and C virus, respectively.
View Article and Find Full Text PDFSteroid-refractory immune mediated hepatitis managed with budesonide in patients with metastatic melanoma: proof of concept and literature review.
Oncologist
January 2025
Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, United States.
Immune checkpoint inhibitors (ICIs) have advanced the treatment of metastatic melanoma. However, some patients develop ICI-associated toxicities like hepatitis (ie, immune-mediated hepatitis; IMH). Although these toxicities usually resolve with steroids, steroid-refractory events may occur, which may be a major source of morbidity and mortality without obviously defined treatment algorithms.
View Article and Find Full Text PDFLong-Term Immunity and Anamnestic Response Following Hepatitis B Vaccination: A Systematic Review and Meta-Analysis.
J Viral Hepat
February 2025
Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, California, USA.
Using a systematic review and meta-analytic approach, this study determined the durability of HBV immunity and the prevalence of anamnestic response to a booster HBV vaccine dose in individuals previously vaccinated with a 3-dose HBV vaccine series as children or adolescents. Two researchers independently searched PubMed, Embase and Cochrane from inception to 6/1/2023 and performed data extraction. Studies that included individuals with significant comorbidities or < 5 years of follow-up were excluded.
View Article and Find Full Text PDFFriend or Foe? Safety and Efficacy of Hepatitis B Viremic Solid Organ Allograft into Seronegative Recipients.
J Am Coll Surg
January 2025
Cincinnati Research in Outcomes and Safety in Surgery (CROSS) Research Group. Department of Surgery, University of Cincinnati College of Medicine, Cincinnati, Ohio.
Background: Long-term outcomes of HBV nucleic acid test (NAT)-positive (+) allograft use in seronegative liver transplant (LT) and kidney transplant (KT) recipients remains unknown despite being incorporated into practice by select centers. This study compares long-term outcomes between HBV NAT+ and NAT-negative (-) allografts in seronegative recipients.
Study Design: All recipients of an HBV core antibody-positive (HBcAb+) LT or KT were prospectively evaluated at a single transplant center from 6/2015-3/2023 and compared by NAT status.
Autoimmune hepatitis, what should be considered when conventional therapies fail?
Rev Esp Enferm Dig
January 2025
Aparato Digestivo, Complejo Asistencial Universitario de León, España.
Autoimmune hepatitis (AIH) is an immune-mediated disease characterised by elevated transaminases, immunoglobulin G and autoantibody positivity. Treatment is based on corticosteroids and azathioprine. Up to 15% of patients will require a second line of treatment, with remission rates after this second line of about 60-75%.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!